---
title: Properties and Antidotes for Anticoagulants Fibrinolytics
---
# Properties and Antidotes for Anticoagulants Fibrinolytics
![image 22-10-02 09 34 21](https://i.imgur.com/8vIwASO.png)

> [[Direct Oral Anticoagulants (DOACs) for NVAF]]

## UFH
* 60–90′, RES ↑ PTT
* Protamine IV 1 mg/100 U UFH (max 50 mg). For infusions, dose to reverse 2× UFH given per h.

## LMWH
* 2–7°, K anti-Xa*
* Protamine reverses ~60%. 1 mg per 1 mg enox.

## Bivalirudin
25′, K ↑ PTT Dialysis

## Argatroban
45′, L ↑ PTT ? Dialysis

## Warfarin
* 36°, L ↑ PT
* No bleeding: vit K 2.5 mg PO if INR >9, o/w no e/o clinical benefit (Blood Adv 2019;3:789)
* Bleeding: vit. K 10 mg IV + either 4F-PCC (KCentra, 25, 35, or 50 U/kg for INR 2–4, 4–6, or >6) or FFP 2–4 U IV q6–8h (slower, more volume)

## Fibrinolytic
* 20′, LK ↓ fbgn
* Cryo, FFP, ± tranexamic or aminocaproic acid
 
## Rivaroxaban Apixaban Edoxaban
* 8–12°, K >L ↑ PT* anti-Xa*
* Andexanet alfa (factor Xa decoy receptor): 800 mg bolus (30 mg/min) → 8 mg/min infusion (½ of above if taking ½ dose DOAC or ≥8 hrs since last dose; NEJM 2019;380:1326); 4F-PCC if andexanet not available

## Dabigatran
* ~12°, K ↑ PTT*
* Idarucizumab: mAb binds drug (NEJM 2017;377:431)
